Targeting homologous recombination deficiency in uterine leiomyosarcoma

BACKGROUND: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some...

Descripción completa

Detalles Bibliográficos
Autores principales: Dall, Genevieve, Vandenberg, Cassandra J., Nesic, Ksenija, Ratnayake, Gayanie, Zhu, Wenying, Vissers, Joseph H. A., Bedő, Justin, Penington, Jocelyn, Wakefield, Matthew J., Kee, Damien, Carmagnac, Amandine, Lim, Ratana, Shield-Artin, Kristy, Milesi, Briony, Lobley, Amanda, Kyran, Elizabeth L., O’Grady, Emily, Tram, Joshua, Zhou, Warren, Nugawela, Devindee, Stewart, Kym Pham, Caldwell, Reece, Papadopoulos, Lia, Ng, Ashley P., Dobrovic, Alexander, Fox, Stephen B., McNally, Orla, Power, Jeremy D., Meniawy, Tarek, Tan, Teng Han, Collins, Ian M., Klein, Oliver, Barnett, Stephen, Olesen, Inger, Hamilton, Anne, Hofmann, Oliver, Grimmond, Sean, Papenfuss, Anthony T., Scott, Clare L., Barker, Holly E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157936/
https://www.ncbi.nlm.nih.gov/pubmed/37143137
http://dx.doi.org/10.1186/s13046-023-02687-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157936/
https://www.ncbi.nlm.nih.gov/pubmed/37143137
http://dx.doi.org/10.1186/s13046-023-02687-0

Ejemplares similares